Inovio Pharmaceuticals
Open
$1.13
Prev. Close
$1.13
High
$1.13
Low
$1.12
Market Snapshot
$60M
-0.7
-3.99
$217.76K
112
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
emptyResult
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Recently from Cashu
Inovio Pharmaceuticals Faces Major Legal Challenges Amid Promising Biotech Innovations
Legal Challenges Loom Over Inovio Pharmaceuticals' Future Inovio Pharmaceuticals, Inc., a prominent player in the biotechnology sector focusing on DNA medicines for HPV-related diseases, cancer, and i…
Inovio Pharmaceuticals Faces Class Action for Alleged Misleading Statements on Manufacturing Capabilities
Inovio Pharmaceuticals Faces Class Action Suit Over Alleged Misleading Statements Inovio Pharmaceuticals, Inc. is currently embroiled in a class action lawsuit alleging violations of federal securitie…
Inovio Pharmaceuticals Faces Class Action Lawsuits Over Securities Fraud Allegations
Inovio Pharmaceuticals Faces Class Action Lawsuits Over Alleged Misrepresentation Inovio Pharmaceuticals, Inc. is currently at the center of multiple class action lawsuits stemming from claims of secu…
Inovio Pharmaceuticals Faces Class Action Lawsuits Over Allegations of Securities Fraud and Misrepresentation
Navigating Legal Waters: Inovio Pharmaceuticals Faces Class Action Lawsuits Inovio Pharmaceuticals finds itself at the center of multiple class action lawsuits following allegations of securities frau…